Search Results

Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, including CAD-9303, a NMDAr-PAM, and MIJ-821, a NMDAr-NAM, which is currently being developed by Novartis under a 2015 license agreement.

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that management will present at the William Blair Biotech Focus Conference on Thursday, August 6, 2020

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2:00-2:25 pm ET.

Cadent Therapeutics announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the following upcoming investor conferences